Factor VIII Inhibitor and Severity of Hemophilia

References
1 Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-John-son M, Shapiro A, Scheibel E, White III G, Lee M. Recombinate Study Group. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83 (09) 2428-2435
2 Hoyer LW. Why do so many haemophilia A patients develop an inhibitor?. Brit J Haematol 1995; 90: 498-501
3 Lusher JM. Human antibodies to recombinant factor VIII in hemophiliacs. J Interferon Res 1994; 14: 173-174
4 Briët E, Rosendaal FR, Kreuz W, Rasi V, Peerlinck K, Vermylen J, Ljung R, Rocina A, Addiego J, Lorenzo JI, Pabinger I. High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products (Letter to the Editor). Thromb Haemost 1994; 72: 162-164
5 De Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Blasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994; 71 (05) 544-547
6 Scharrer I, Neutzling O. Incidence of inhibitors in haemophiliacs. A review of the literature. Blood Coagulation and Fibrinolysis 1993; 4: 753-758
7 Green D, Di Michele DM. Hemophilia: factor VIII deficiency. In: Thrombosis and Hemorrhage Loscalzo J, Schafer AI. eds. Blackwell Scientific Publications; 683-687
8 Aledort LM, Haschmeyer RH, Pettersson H. the Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcome for severe factor-VUI-deficient haemophiliacs. J Internal Med 1994; 236: 391-399
9 Nilsson IM, Bemtorp E, Ljung R, Löfqvist T, Pettersson H. Prophylactic treatment of severe hemophilia A and B can prevent joint disability. Sem Hematol 1994; 31 (02) (Suppl. 02) 5-9
10 Walker I, Pai M, Akabutu J, Ritchie B, Growe G, Poon M-C, Card R, Ali K, Israels S, Teitel J, Garvey B, Blanchette V, Giles A, Lillicrap D, Drouin J, Luke B, Gill K, Herst J, Lépine-Martin M, Inwood M, Rivard G, Strawczynski H, Jobin F, Demers C, Jardine L, Whitman L, Ingram L, Robinson S, Rubin S, Scully M-F, Dolan S, Ross E. The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates. Transfusion 1995; 35: 548-551
11 Brettler DB, Levine PH. Clinical manifestations and therapy of inherited coagulation factor deficiencies. In: Hemostasis and Thrombosis Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. eds. J.B. Lippincott Company; Philadelphia, PA: 1994: 169-183
12 Berntorp E, Boulyjenkov V, Brettler D, Chandy M, Jones P, Lee C, Lusher J, Mannucci P, Peake I, Rickard K, Seremetis S. Modem treatment of haemophilia. Bulletin of the WHO 1995; 73 (05) 691-701
13 Gill JC. Therapy of factor VIII deficiency. Semin Thromb Haemost 1993; 19 (01) 1-12
14 Amano K, Arai M, Koshihara K, Suzuki T, Kagawa K, Nishida Y, Fukutake K. Autoantibody to factor VIII that has less reactivity to factor VUI/von Willebrand factor complex. Amer J Hematol 1995; 49: 310-317
15 Rock G, Adamkiewitz T, Blanchette V, Poon A, Sparling C. Acquired von Willebrand factor deficiency during high dose infusion of recombinant factor VIII. Blood 1995 86. Abstract 760
16 Vermylen J, Peerlinck K. Epidemic of factor VIII inhibitors linked to factor VIII-P (letter). Acta Clin Belg 1991; 46: 419
17 Paul-Ehrlich-Institut press release of Sept. 7, 1995. Paul-Ehrlich-Institut zieht Gerinnungspraparat zurück (Paul-Ehrlich Institute withdraws coagulation product)
18 Yee TT, Williams MD, Hill FGH, Lee CA, Pasi KJ. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to only a single intermediate purity factor VIII product. Blood 1995 86. Abstract 759
19 Schimpf K, Schwarz H-P, Kunschak M. Zero Incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Thromb Haemost 1995; 73 (03) 553-555